{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:15:31Z","timestamp":1793330131517,"version":"4.5.0"},"reference-count":64,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01AI099959"],"award-info":[{"award-number":["U01AI099959"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI068636"],"award-info":[{"award-number":["UM1AI068636"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["2R01AI098472"],"award-info":[{"award-number":["2R01AI098472"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["K23MH114760"],"award-info":[{"award-number":["K23MH114760"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1159068"],"award-info":[{"award-number":["OPP1159068"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Background<\/jats:title><jats:p>Oral pre-exposure prophylaxis (PrEP) is highly effective for HIV prevention, but data are limited on HIV incidence among PrEP users in generalized epidemic settings, particularly outside of selected risk groups. We performed a population-based PrEP study in rural Kenya and Uganda and sought to evaluate both changes in HIV incidence and clinical and virologic outcomes following seroconversion on PrEP.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methods and findings<\/jats:title><jats:p>During population-level HIV testing of individuals \u226515 years in 16 communities in the Sustainable East Africa Research in Community Health (SEARCH) study (NCT01864603), we offered universal access to PrEP with enhanced counseling for persons at elevated HIV risk (based on serodifferent partnership, machine learning\u2013based risk score, or self-identified HIV risk). We offered rapid or same-day PrEP initiation and flexible service delivery with follow-up visits at facilities or community-based sites at 4, 12, and every 12 weeks up to week 144. Among participants with incident HIV infection after PrEP initiation, we offered same-day antiretroviral therapy (ART) initiation and analyzed HIV RNA, tenofovir hair concentrations, drug resistance, and viral suppression (&lt;1,000 c\/ml based on available assays) after ART start. Using Poisson regression with cluster-robust standard errors, we compared HIV incidence among PrEP initiators to incidence among propensity score\u2013matched recent historical controls (from the year before PrEP availability) in 8 of the 16 communities, adjusted for risk group. Among 74,541 individuals who tested negative for HIV, 15,632\/74,541 (21%) were assessed to be at elevated HIV risk; 5,447\/15,632 (35%) initiated PrEP (49% female; 29% 15\u201324 years; 19% in serodifferent partnerships), of whom 79% engaged in \u22651 follow-up visit and 61% self-reported PrEP adherence at \u22651 visit. Over 7,150 person-years of follow-up, HIV incidence was 0.35 per 100 person-years (95% confidence interval [CI] 0.22\u20130.49) among PrEP initiators. Among matched controls, HIV incidence was 0.92 per 100 person-years (95% CI 0.49\u20131.41), corresponding to 74% lower incidence among PrEP initiators compared to matched controls (adjusted incidence rate ratio [aIRR] 0.26, 95% CI 0.09\u20130.75;<jats:italic>p<\/jats:italic>= 0.013). Among women, HIV incidence was 76% lower among PrEP initiators versus matched controls (aIRR 0.24, 95% CI 0.07\u20130.79;<jats:italic>p<\/jats:italic>= 0.019); among men, HIV incidence was 40% lower, but not significantly so (aIRR 0.60, 95% CI 0.12\u20133.05;<jats:italic>p<\/jats:italic>= 0.54). Of 25 participants with incident HIV infection (68% women), 7\/25 (28%) reported taking PrEP \u226430 days before HIV diagnosis, and 24\/25 (96%) started ART. Of those with repeat HIV RNA after ART start, 18\/19 (95%) had &lt;1,000 c\/ml. One participant with viral non-suppression was found to have transmitted viral resistance, as well as emtricitabine resistance possibly related to PrEP use. Limitations include the lack of contemporaneous controls to assess HIV incidence without PrEP and that plasma samples were not archived to assess for baseline acute infection.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Conclusions<\/jats:title><jats:p>Population-level offer of PrEP with rapid start and flexible service delivery was associated with 74% lower HIV incidence among PrEP initiators compared to matched recent controls prior to PrEP availability. HIV infections were significantly lower among women who started PrEP. Universal HIV testing with linkage to treatment and prevention, including PrEP, is a promising approach to accelerate reductions in new infections in generalized epidemic settings.<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Trial registration<\/jats:title><jats:p>ClinicalTrials.gov<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01864603\" xlink:type=\"simple\">NCT01864603<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pmed.1003492","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T19:01:34Z","timestamp":1612897294000},"page":"e1003492","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":72,"title":["HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7297-175X","authenticated-orcid":true,"given":"Catherine A.","family":"Koss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane V.","family":"Havlir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Ayieko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalsone","family":"Kwarisiima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0265-3174","authenticated-orcid":true,"given":"Jane","family":"Kabami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5860-8081","authenticated-orcid":true,"given":"Gabriel","family":"Chamie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4762-0728","authenticated-orcid":true,"given":"Mucunguzi","family":"Atukunda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Mwinike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9467-0950","authenticated-orcid":true,"given":"Florence","family":"Mwangwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5594-0310","authenticated-orcid":true,"given":"Asiphas","family":"Owaraganise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winter","family":"Olilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0074-2720","authenticated-orcid":true,"given":"Katherine","family":"Snyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1791-7870","authenticated-orcid":true,"given":"Benard","family":"Awuonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1109-6039","authenticated-orcid":true,"given":"Tamara D.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Nugent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1809-3762","authenticated-orcid":true,"given":"Lillian B.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7622-6562","authenticated-orcid":true,"given":"Carina","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8519-7409","authenticated-orcid":true,"given":"Hideaki","family":"Okochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0769-9518","authenticated-orcid":true,"given":"Kevin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5615-1164","authenticated-orcid":true,"given":"Carol S.","family":"Camlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7025-1994","authenticated-orcid":true,"given":"Monica","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8654-6634","authenticated-orcid":true,"given":"Craig R.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Bukusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7237-2119","authenticated-orcid":true,"given":"Edwin D.","family":"Charlebois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya L.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses R.","family":"Kamya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3730-410X","authenticated-orcid":true,"given":"Laura B.","family":"Balzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,2,9]]},"reference":[{"key":"pmed.1003492.ref001","unstructured":"UNAIDS. Global AIDS update: Seizing the moment: Tacking entrenched inequalities to end epidemics. Geneva, Switzerland; 2020."},{"issue":"5","key":"pmed.1003492.ref002","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"JM Baeten","year":"2012","journal-title":"N Engl J Med"},{"issue":"27","key":"pmed.1003492.ref003","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"RM Grant","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"pmed.1003492.ref004","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1600693","article-title":"Antiretroviral therapy for the prevention of HIV-1 transmission","volume":"375","author":"MS Cohen","year":"2016","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"pmed.1003492.ref005","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1097\/QAI.0000000000002200","article-title":"Getting to Zero San Francisco: A collective impact approach","volume":"82","author":"SP Buchbinder","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"pmed.1003492.ref006","doi-asserted-by":"crossref","first-page":"e629","DOI":"10.1016\/S2352-3018(18)30215-7","article-title":"Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study","volume":"5","author":"AE Grulich","year":"2018","journal-title":"Lancet HIV"},{"issue":"8","key":"pmed.1003492.ref007","doi-asserted-by":"crossref","first-page":"e1002099","DOI":"10.1371\/journal.pmed.1002099","article-title":"Integrated delivery of antiretroviral treatment and pre-exposure prophylaxis to HIV-1-serodiscordant couples: a prospective implementation study in Kenya and Uganda","volume":"13","author":"JM Baeten","year":"2016","journal-title":"PLoS Med"},{"key":"pmed.1003492.ref008","unstructured":"Celum C, Mgodi N, Bekker LG, Hosek S, Donnell D, Anderson P, et al. editors. PrEP adherence and effect of drug level feedback among young African women in HPTN 082. 10th IAS Conference on HIV Science; 2019; Mexico City, Mexico."},{"key":"pmed.1003492.ref009","doi-asserted-by":"crossref","first-page":"100541","DOI":"10.1016\/j.eclinm.2020.100541","article-title":"PrEP uptake and adherence in relation to HIV-1 incidence among Kenyan men who have sex with men","volume":"26","author":"EW Wahome","year":"2020","journal-title":"EClinicalMedicine"},{"key":"pmed.1003492.ref010","doi-asserted-by":"crossref","first-page":"e25208","DOI":"10.1002\/jia2.25208","article-title":"Early antiretroviral therapy and daily pre-exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study","volume":"21","author":"A Mboup","year":"2018","journal-title":"J Int AIDS Soc"},{"issue":"3","key":"pmed.1003492.ref011","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1056\/NEJMoa1809866","article-title":"HIV testing and treatment with the use of a community health approach in rural Africa","volume":"381","author":"DV Havlir","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"pmed.1003492.ref012","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1016\/S2352-3018(19)30433-3","article-title":"Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study","volume":"7","author":"CA Koss","year":"2020","journal-title":"Lancet HIV"},{"issue":"12","key":"pmed.1003492.ref013","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/cid\/ciy390","article-title":"Early adopters of Human Immunodeficiency Virus preexposure prophylaxis in a population-based combination prevention study in rural Kenya and Uganda","volume":"67","author":"CA Koss","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pmed.1003492.ref014","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/S2352-3018(15)00251-9","article-title":"A hybrid mobile approach for population-wide HIV testing in rural east Africa: an observational study","volume":"3","author":"G Chamie","year":"2016","journal-title":"Lancet HIV"},{"issue":"2","key":"pmed.1003492.ref015","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/sim.7296","article-title":"Constrained binary classification using ensemble learning: an application to cost-efficient targeted PrEP strategies","volume":"37","author":"SEARCH Collaboration","year":"2018","journal-title":"Stat Med"},{"key":"pmed.1003492.ref016","unstructured":"Chamie G, Sang N, Kwarisiima D, Kabami J, Bagala I, Atukunda M, et al. Yield of HIV testing and re-engagement of key populations in Uganda and Kenya. Conference on Retroviruses and Opportunistic Infections. Seattle, Washington, USA; 2019."},{"key":"pmed.1003492.ref017","volume-title":"Guidelines on use of antiretroviral drugs for treating and preventing HIV infection in Kenya 2016","author":"Ministry of Health National AIDS and STI Control Programme","year":"2016"},{"key":"pmed.1003492.ref018","unstructured":"World Health Organization. WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection. Module 6: Pharmacists. Geneva, Switzerland; 2017."},{"issue":"3","key":"pmed.1003492.ref019","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/09540120050042891","article-title":"Self-reported adherence to antiretroviral medication among participants in HIV clinical trials: the AACTG adherence instruments","volume":"12","author":"MA Chesney","year":"2000","journal-title":"AIDS Care"},{"key":"pmed.1003492.ref020","unstructured":"Uganda Ministry of Health. Consolidated guidelines for prevention and treatment of HIV in Uganda. 2016."},{"key":"pmed.1003492.ref021","volume-title":"Guidelines on use of antiretroviral drugs for treating and preventing HIV infection in Kenya 2018","author":"Ministry of Health National AIDS and STI Control Programme","year":"2018"},{"issue":"1","key":"pmed.1003492.ref022","doi-asserted-by":"crossref","first-page":"e83736","DOI":"10.1371\/journal.pone.0083736","article-title":"Strong relationship between oral dose and tenofovir hair levels in a randomized trial: Hair as a potential adherence measure for pre-exposure prophylaxis (PrEP)","volume":"9","author":"AY Liu","year":"2014","journal-title":"PLoS ONE"},{"issue":"2","key":"pmed.1003492.ref023","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/cid\/cix755","article-title":"Comparison of measures of adherence to Human Immunodeficiency Virus preexposure prophylaxis among adolescent and young men who have sex with men in the United States","volume":"66","author":"CA Koss","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"7","key":"pmed.1003492.ref024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v042.i07","article-title":"Multivariate and propensity score matching software with automated balance optimization: The Matching package for R","volume":"42","author":"JS Sekhon","year":"2011","journal-title":"J Stat Softw"},{"key":"pmed.1003492.ref025","doi-asserted-by":"crossref","first-page":"Article25","DOI":"10.2202\/1544-6115.1309","article-title":"Super learner","volume":"6","author":"MJ van der Laan","year":"2007","journal-title":"Stat Appl Genet Mol Biol"},{"issue":"2","key":"pmed.1003492.ref026","doi-asserted-by":"crossref","first-page":"e25455","DOI":"10.1002\/jia2.25455","article-title":"What do the Universal Test and Treat trials tell us about the path to HIV epidemic control?","volume":"23","author":"D Havlir","year":"2020","journal-title":"J Int AIDS Soc"},{"issue":"6","key":"pmed.1003492.ref027","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"JM Marrazzo","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"pmed.1003492.ref028","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"L Van Damme","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"pmed.1003492.ref029","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/QAI.0000000000001939","article-title":"A Patient-centered multicomponent strategy for accelerated linkage to care following community-wide HIV testing in rural Uganda and Kenya","volume":"80","author":"J Ayieko","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pmed.1003492.ref030","unstructured":"Mikati T, Jamison K, Daskalakis DC. Immediate PrEP initiation at New York City sexual health clinics. Conference on Retroviruses and Opportunistic Infections. Seattle, Washington; 2019."},{"issue":"7","key":"pmed.1003492.ref031","doi-asserted-by":"crossref","first-page":"ofz310","DOI":"10.1093\/ofid\/ofz310","article-title":"Same-Day HIV pre-exposure prophylaxis (PrEP) initiation during drop-in sexually transmitted diseases clinic appointments Is a highly acceptable, feasible, and safe model that engages individuals at risk for HIV into PrEP care","volume":"6","author":"KF Kamis","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"pmed.1003492.ref032","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/QAD.0000000000000647","article-title":"Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm","volume":"29","author":"JE Haberer","year":"2015","journal-title":"AIDS"},{"issue":"8","key":"pmed.1003492.ref033","doi-asserted-by":"crossref","first-page":"e25588","DOI":"10.1002\/jia2.25588","article-title":"Uptake and retention on HIV pre-exposure prophylaxis among key and priority populations in South-Central Uganda","volume":"23","author":"J Kagaayi","year":"2020","journal-title":"J Int AIDS Soc"},{"issue":"Suppl 3","key":"pmed.1003492.ref034","doi-asserted-by":"crossref","first-page":"e25537","DOI":"10.1002\/jia2.25537","article-title":"Using a HIV prevention cascade for identifying missed opportunities in PrEP delivery in Kenya: results from a programmatic surveillance study","volume":"23","author":"D Were","year":"2020","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"pmed.1003492.ref035","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/QAI.0000000000002481","article-title":"Model-based predictions of HIV incidence among African women using HIV risk behaviors and community-level data on male HIV prevalence and viral suppression","volume":"85","author":"JR Moore","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pmed.1003492.ref036","unstructured":"Donnell D, Beesham I, Welch JD, Heffron R, Pleaner M, Kidoguchi L, et al. Incorporating PrEP into standard of prevention in a clinical trial is associated with reduced HIV incidence: Evidence from the ECHO Trial. 23rd International AIDS Conference (AIDS 2020: Virtual), 2020."},{"issue":"3","key":"pmed.1003492.ref037","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1814556","article-title":"Effect of universal testing and treatment on HIV incidence\u2014HPTN 071 (PopART)","volume":"381","author":"RJ Hayes","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"pmed.1003492.ref038","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1812281","article-title":"Universal testing, expanded treatment, and incidence of HIV infection in Botswana","volume":"381","author":"J Makhema","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"pmed.1003492.ref039","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1702150","article-title":"HIV prevention efforts and incidence of HIV in Uganda","volume":"377","author":"MK Grabowski","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"pmed.1003492.ref040","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"MC Thigpen","year":"2012","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"pmed.1003492.ref041","doi-asserted-by":"crossref","first-page":"e25526","DOI":"10.1002\/jia2.25526","article-title":"Shifting the narrative: from \u201cthe missing men\u201d to \u201cwe are missing the men\u201d","volume":"23","author":"A Grimsrud","year":"2020","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"pmed.1003492.ref042","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/S2352-3018(16)30186-2","article-title":"Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study","volume":"4","author":"T de Oliveira","year":"2017","journal-title":"Lancet HIV"},{"key":"pmed.1003492.ref043","article-title":"Mapping of HIV-1C transmission networks reveals extensive spread of viral lineages across villages in Botswana treatment-as-prevention trial","author":"V Novitsky","year":"2020","journal-title":"J Infect Dis"},{"issue":"22","key":"pmed.1003492.ref044","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","article-title":"Use of a vaginal ring containing dapivirine for HIV-1 prevention in women","volume":"375","author":"JM Baeten","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"pmed.1003492.ref045","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","article-title":"Safety and efficacy of dapivirine vaginal ring for HIV prevention in women","volume":"375","author":"A Nel","year":"2016","journal-title":"N Engl J Med"},{"key":"pmed.1003492.ref046","unstructured":"Landovitz RJ, Donnell D, Clement M, Hanscom B, Cottle L, Coelho L, et al. HPTN 083 Final Results: Pre-exposure prophylaxis containing long-acting injectable cabotegravir is safe and highly effective for cisgender men and transgender women who have sex with men. 23rd International AIDS Conference (AIDS 2020: Virtual), 2020."},{"issue":"2","key":"pmed.1003492.ref047","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/QAD.0000000000000102","article-title":"CD4(+) cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis","volume":"28","author":"LI Chirwa","year":"2014","journal-title":"AIDS"},{"issue":"3","key":"pmed.1003492.ref048","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/QAD.0000000000000556","article-title":"Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women","volume":"29","author":"RM Grant","year":"2015","journal-title":"AIDS"},{"issue":"6","key":"pmed.1003492.ref049","doi-asserted-by":"crossref","first-page":"e0178594","DOI":"10.1371\/journal.pone.0178594","article-title":"HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial","volume":"12","author":"SA Riddler","year":"2017","journal-title":"PLoS ONE"},{"key":"pmed.1003492.ref050","unstructured":"World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva, Switzerland; 2017."},{"issue":"2","key":"pmed.1003492.ref051","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1016\/S2352-3018(19)30404-7","article-title":"Dean Street Collaborative Group. Antiretroviral resistance and management after pre-exposure to prophylaxis","volume":"7","author":"V Tittle","year":"2020","journal-title":"Lancet HIV"},{"issue":"4","key":"pmed.1003492.ref052","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/S2352-3018(19)30402-3","article-title":"Point-of-care HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM): findings from an open-label, non-inferiority, randomised controlled trial","volume":"7","author":"PK Drain","year":"2020","journal-title":"Lancet HIV"},{"issue":"5","key":"pmed.1003492.ref053","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMc1611639","article-title":"Multidrug-resistant HIV-1 infection despite preexposure prophylaxis","volume":"376","author":"DC Knox","year":"2017","journal-title":"N Engl J Med"},{"key":"pmed.1003492.ref054","article-title":"Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report","author":"SE Cohen","year":"2018","journal-title":"Lancet HIV"},{"issue":"6","key":"pmed.1003492.ref055","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/cid\/ciy321","article-title":"Acquisition of multidrug-resistant Human Immunodeficiency Virus type 1 infection in a patient taking preexposure prophylaxis","volume":"67","author":"DJ Colby","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"11","key":"pmed.1003492.ref056","doi-asserted-by":"crossref","first-page":"e522","DOI":"10.1016\/S2352-3018(17)30132-7","article-title":"Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report","volume":"4","author":"E Hoornenborg","year":"2017","journal-title":"Lancet HIV"},{"issue":"4","key":"pmed.1003492.ref057","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1097\/QAI.0000000000001534","article-title":"Newly acquired infection with multidrug-resistant HIV-1 in a patient adherent to preexposure prophylaxis","volume":"76","author":"M Markowitz","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pmed.1003492.ref058","article-title":"Use of drug-level testing and single-genome sequencing to unravel a case of HIV seroconversion on PrEP","author":"MA Spinelli","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"9","key":"pmed.1003492.ref059","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0000000000001825","article-title":"Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination","volume":"32","author":"JT Thaden","year":"2018","journal-title":"AIDS"},{"issue":"11","key":"pmed.1003492.ref060","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3018(16)30153-9","article-title":"Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study","volume":"3","author":"M Gandhi","year":"2016","journal-title":"Lancet HIV"},{"issue":"1","key":"pmed.1003492.ref061","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01710-17","article-title":"Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy","volume":"62","author":"PL Anderson","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pmed.1003492.ref062","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/aid.2015.0182","article-title":"Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066)","volume":"32","author":"CW Hendrix","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"3","key":"pmed.1003492.ref063","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1097\/QAI.0000000000001141","article-title":"Implementation and Operational Research: Cost and efficiency of a hybrid mobile multidisease testing approach with high HIV testing coverage in East Africa","volume":"73","author":"W Chang","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"pmed.1003492.ref064","doi-asserted-by":"crossref","first-page":"21514","DOI":"10.7448\/IAS.20.1.21514","article-title":"Evaluating the feasibility and uptake of a community-led HIV testing and multi-disease health campaign in rural Uganda","volume":"20","author":"J Kabami","year":"2017","journal-title":"J Int AIDS Soc"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003492","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T21:19:33Z","timestamp":1697836773000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003492"}},"subtitle":[],"editor":[{"given":"Marie-Louise","family":"Newell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,9]]},"references-count":64,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1003492","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,9]]}}}